Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Sushmita Gordhandas

Gynecologic Oncology Fairfax, VA Medical Doctor

NPI 1093178121 CMS profile 11420579

8081 Innovation Park Dr Ste 775, Fairfax, VA 22031

Open in the dashboard

General payments

$3,567

54 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sushmita Gordhandas of Fairfax, VA is reported in the CMS Open Payments database as having received $3,567 across 54 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,860 43
2024 General $156 6
2023 General $124 1
2022 General $427 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sushmita Gordhandas
  • Gynecologic Oncology median
  • Middle half of Gynecologic Oncology
  • National median

In program year 2025, general payments to Sushmita Gordhandas were reported at $2,860. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.

Show as a table
Year Sushmita Gordhandas Gynecologic Oncology median Middle half National median
2019 $0 $287 $113–$1,548 $163
2020 $0 $223 $59–$2,164 $114
2021 $0 $193 $68–$1,139 $132
2022 $427 $252 $90–$1,151 $149
2023 $124 $281 $102–$1,419 $160
2024 $156 $308 $108–$1,502 $164
2025 $2,860 $305 $111–$1,499 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Medical Device Business Services, Inc. $1,202 12 payments
  2. Intuitive Surgical, Inc. $958 5 payments
  3. AstraZeneca Pharmaceuticals LP $485 6 payments
  4. GlaxoSmithKline, LLC. $200 4 payments
  5. Davol Inc. $140 5 payments
  6. AbbVie, Inc. $124 5 payments
  7. Merck Sharp & Dohme Corporation $104 4 payments
  8. Pfizer Inc. $58 2 payments
  9. Integra LifeSciences Corporation $52 2 payments
  10. Ethicon US, LLC $46 2 payments
  11. Other $200 7 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,857 46 payments
  2. Travel and Lodging $1,710 8 payments
Products named General payments · program years 2022–2025
  1. Harmonic $1,202 12 payments
  2. Da Vinci Surgical System $958 5 payments
  3. LYNPARZA $442 5 payments
  4. ZEJULA $200 4 payments
  5. ELAHERE $124 5 payments
  6. ARISTA $116 4 payments
  7. JEMPERLI $75 3 payments
  8. TIVDAK $58 2 payments
  9. KEYTRUDA $57 2 payments
  10. CODMAN CERTAS $52 2 payments
  11. Other $400 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

54 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecologic Oncology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record